Feline Sino-Nasal and Sino-Orbital Aspergillosis

Feline upper respiratory tract aspergillosis (URTA) is an emerging fungal infectious disease that occurs in two anatomically distinct forms: sino-nasal aspergillosis (SNA), which is confined to the nasal cavity and paranasal sinuses, and sino-orbital aspergillosis (SOA), which extends beyond the sinuses to involve the orbit and periorbital tissues [1]. The disease is caused primarily by Aspergillus species, with the cryptic species Aspergillus felis frequently implicated as an important emerging pathogen [1][2]. Unlike aspergillosis in dogs or immunocompromised humans, feline URTA often affects cats without obvious underlying immunosuppression, making its pathogenesis and host susceptibility factors incompletely understood [2]. The condition is considered an emerging infectious disease of cats, with increasing recognition in the veterinary literature over the past decade [2][3].

Causative Organisms: Feline URTA is caused by Aspergillus species of the section Fumigati. While Aspergillus fumigatus (sensu stricto) can be involved, the cryptic species Aspergillus felis has been identified as a particularly important and frequently isolated pathogen in affected cats [1][2]. A. felis belongs to a cluster of cryptic species morphologically similar to A. fumigatus but distinguishable by molecular methods. Other Aspergillus species including A. niger and A. flavus have also been implicated [2][3].

Route of Infection: Aspergillus conidia (spores) are ubiquitous in the environment, and infection is believed to occur via inhalation of airborne spores into the nasal cavity [1]. Computed tomography (CT) studies support the nasal cavity and cribriform plate as primary routes of fungal invasion [1]. In SNA, infection remains limited to the nasal passages and paranasal sinuses with characteristic fungal plaque formation and turbinate destruction. In SOA, the fungus extends through the orbit via the retrobulbar space, most likely through direct extension from the caudal nasal cavity or pterygopalatine fossa rather than hematogenous spread [1].

Pathological Mechanism: The organism invades sinonasal and/or orbital soft tissues, producing characteristic fungal plaques composed of hyphal mats and inciting a destructive inflammatory response. CT imaging reveals osteolysis (bone destruction) of the turbinates, sinus walls, cribriform plate, and orbital bones, consistent with invasive local disease [1]. The pathogenesis is notable because it appears to occur in immunocompetent cats, suggesting that local mucosal immune defenses or specific host-pathogen interactions may be critical determinants of disease susceptibility [2]. The relationship between the infecting Aspergillus isolate (species, virulence factors) and clinical outcome is not yet fully characterized [1].

Immunological Response: Cats with URTA mount detectable Aspergillus-specific immunoglobulin responses. Aspergillus-specific IgG (As-IgG) is detectable by both agar gel double immunodiffusion (AGID) and indirect IgG ELISA in affected cats [2]. Additionally, Aspergillus-specific IgA (As-IgA) has been detected in serum, suggesting a role for mucosal immunity in the host response; however, As-IgA does not appear to offer significant additional diagnostic sensitivity over As-IgG testing [3].

Diagnosis of feline sino-nasal and sino-orbital aspergillosis requires integration of clinical, imaging, serological, cytological, and microbiological findings.

Clinical Evaluation: Suspicion is raised by chronic, treatment-refractory rhinitis/sinusitis, epistaxis, or progressive exophthalmos in a cat. Thorough ophthalmic examination is essential to differentiate SNA from SOA.

Imaging — Computed Tomography (CT): CT is the imaging modality of choice and provides detailed assessment of the extent of disease [1]. CT findings in SNA include soft tissue opacity within nasal passages and sinuses, turbinate lysis, and evidence of fungal plaque. In SOA, CT reveals orbital soft tissue masses, retrobulbar involvement, and variable osteolysis of the orbital bones and walls [1]. CT is critical for surgical planning and for determining the route and extent of fungal extension [1].

Rhinoscopy and Biopsy: Rhinoscopy allows direct visualization of characteristic white-to-grey fungal plaques within the nasal cavity and sample collection. Biopsy for histopathology demonstrating branching septate hyphae with tissue invasion confirms the diagnosis. Fungal culture of biopsy or swab material allows species identification.

Cytology: Impression smears or cytological preparations from nasal discharge or biopsies may reveal fungal hyphae, though sensitivity is variable.

Serology:

• ·Agar Gel Double Immunodiffusion (AGID): Detection of Aspergillus-specific precipitating antibodies is diagnostically useful; however, sensitivity varies with the antigen preparation used [2].
• ·Indirect IgG ELISA: As-IgG ELISA demonstrates utility for diagnosis of feline URTA. An aspergillin antigen derived from A. fumigatus, A. niger, and A. flavus can detect antibodies against cryptic Aspergillus spp. including A. felis, expanding its diagnostic applicability [2].
• ·Indirect IgA ELISA: Serum As-IgA is detectable in cats with URTA, but As-IgA testing does not provide significant additional diagnostic benefit beyond As-IgG testing alone [3]. As-IgA may be detectable even in some cats with negative As-IgG results, offering limited incremental value [3].

Galactomannan Assay: Galactomannan (a fungal cell wall antigen) detection may be considered as an adjunct test, though its sensitivity and specificity have not been as thoroughly evaluated in cats as in human medicine.

Molecular Identification: PCR-based molecular typing is required to definitively identify cryptic species such as A. felis, distinguishing them from A. fumigatus sensu stricto [1][2].

Laboratory Findings: Routine clinicopathological abnormalities are not pathognomonic but may include:

• ·Complete Blood Count (CBC): Variable leukocytosis (neutrophilia) reflecting chronic infection; mild non-regenerative anemia (anemia of chronic disease) may be present.
• ·Serum Biochemistry: Hyperglobulinemia (elevated GLOB) reflecting a polyclonal or monoclonal gammopathy associated with chronic antigenic stimulation; albumin (ALB) may be mildly decreased; other parameters (BUN, CREA, ALT, TBIL) are generally within normal limits unless concurrent disease is present.
• ·Platelet count (PLT): Generally within normal limits.
• ·HCT: May be mildly reduced consistent with anemia of chronic disease.

Management of feline sino-nasal and sino-orbital aspergillosis requires a multimodal approach combining antifungal therapy with surgical debridement where feasible.

Antifungal Pharmacotherapy:

• ·

  Systemic Triazole Antifungals are the cornerstone of treatment:

  • ·Itraconazole has traditionally been used in feline aspergillosis at doses of approximately 5–10 mg/kg PO once daily or divided. Bioavailability of the capsule formulation is variable; the oral solution formulation is preferred for more reliable absorption.
  • ·Voriconazole is active against Aspergillus spp. including cryptic species such as A. felis, but its use in cats is complicated by significant species-specific toxicity (neurological signs, visual disturbances) and is generally avoided or used with extreme caution.
  • ·Posaconazole offers broad-spectrum activity and may be considered in refractory cases, though clinical data in cats remain limited.
  • ·Terbinafine (an allylamine antifungal) has been used in combination with triazoles in some refractory cases given its distinct mechanism of action.
  • ·Duration of antifungal therapy is typically prolonged — often many months — and is guided by clinical response, repeat CT imaging, and serological monitoring.
• ·

  Topical Antifungal Infusion:

  • ·In SNA cases, non-invasive topical antifungal infusion (e.g., clotrimazole or enilconazole delivered via nasal flush under anesthesia) has been used with some success as an adjunct to systemic therapy. This technique delivers high local drug concentrations directly to the fungal plaques.

Surgical Intervention:

• ·Debridement and plaque removal via rhinoscopy or surgical rhinotomy is an important component of management, particularly for SNA. Removing fungal plaque burden reduces the infectious load and may improve penetration of systemic antifungals.
• ·In SOA, orbital exploration and debridement may be necessary; however, exenteration (surgical removal of the orbital contents) is sometimes required in advanced cases with extensive orbital involvement, though this carries significant morbidity.
• ·Sinonasal surgery also facilitates sample collection for culture, sensitivity testing, and molecular speciation.

Supportive Care:

• ·Nutritional support (assisted feeding if anorexia is present) is important in debilitated cats.
• ·Management of secondary bacterial infections with appropriate antibiotics based on culture and sensitivity.
• ·Ophthalmic supportive care (lubricants, anti-inflammatory therapy) for cats with orbital involvement.
• ·Anti-inflammatory medications (NSAIDs or low-dose corticosteroids) may be used judiciously to manage inflammation-mediated tissue damage, though corticosteroid use requires caution in fungal disease.

Antifungal Susceptibility: Species identification (including differentiation of A. felis from A. fumigatus sensu stricto) is clinically important because minimum inhibitory concentrations (MICs) vary among cryptic species, potentially influencing antifungal drug selection [1][2].

The prognosis for feline URTA is guarded to poor, particularly for the SOA form, which involves more extensive tissue destruction and is more difficult to treat surgically.

Survival and Outcome: The referenced literature focuses primarily on diagnostic aspects (CT features [1], serological diagnosis [2][3]) rather than reporting explicit survival statistics or case-fatality rates. Accordingly, precise mortality percentages cannot be directly extracted from these cited studies. However, the literature consistently characterizes URTA — especially SOA — as a serious, life-threatening disease with a guarded prognosis.

Key Prognostic Factors:

• ·Anatomical form: SNA carries a relatively better prognosis than SOA, as disease is more localized and more amenable to topical and surgical treatment. SOA, with its orbital extension and extensive osteolysis [1], is associated with a worse prognosis.
• ·Extent of osteolysis: Greater bone destruction on CT (e.g., cribriform plate lysis, orbital wall destruction) is associated with a poorer prognosis and higher likelihood of treatment failure [1].
• ·Causative species: The emergence of A. felis as a distinct pathogen raises questions about potential differences in virulence and antifungal susceptibility compared to A. fumigatus sensu stricto [1][2].
• ·Response to antifungal therapy: Many cats require prolonged treatment (months to years), and relapses are common. Some cats fail to respond adequately to medical and surgical management.
• ·Serological monitoring: Declining As-IgG and As-IgA titers over the course of treatment may serve as indicators of therapeutic response [2][3].

Data limitation: No peer-reviewed survival statistics (e.g., median survival time, 1-year survival rate) for feline SNA or SOA were explicitly reported in the references cited above [1][2][3]. Clinicians should consult the most current specialist literature and case series for updated outcome data. Based on the broader clinical literature, overall long-term cure rates are considered low, particularly for SOA, with many cats ultimately euthanized due to disease progression or poor quality of life.

There are currently no vaccines available for feline aspergillosis, and specific proven prevention strategies are limited given the incomplete understanding of why certain cats develop URTA while most exposed to environmental Aspergillus conidia do not.

Environmental Management:

• ·Minimizing cats' exposure to environments with high fungal spore burdens (e.g., compost heaps, decaying organic matter, dusty environments, construction sites) is a rational precaution, though the evidence directly linking specific environmental exposures to feline URTA is not established in the cited literature.
• ·Maintaining good indoor air quality and avoiding damp, moldy living conditions may theoretically reduce spore load.

Immune Status:

• ·Identifying and managing any underlying conditions that may compromise immune function (e.g., FIV, FeLV infection, concurrent disease, or immunosuppressive drug therapy) is advisable, as immunosuppression may predispose cats to opportunistic fungal infections.
• ·However, it is important to note that many cats with URTA do not have identifiable immunosuppression [2], limiting the utility of immune management as a sole preventive strategy.

Early Veterinary Attention:

• ·Prompt veterinary evaluation of chronic or refractory nasal signs (persistent nasal discharge, epistaxis, facial swelling) allows earlier diagnosis and treatment initiation, which may improve outcomes even if true prevention is not achievable.

No specific vaccination, chemoprophylaxis, or husbandry intervention has been validated for prevention of feline aspergillosis in the peer-reviewed literature.